Use of anti third party central memory T cells for anti-leukemia/lymphoma treatment

US9421228B2 · kind B2 · utility

Assignee

• YEDA RESEARCH AND DEVELOPMENT CO. LTD. · IL

Inventors

• Yair Reisner · Jaffa, IL
• Assaf Lask · Rehovot, IL
• Eran Ophir · Rehovot, IL
• Noga Or-Geva · Rehovot, IL
• Adva Cohen · Rehovot, IL
• Ran Afik · Rehovot, IL
• Esther Bachar-Lustig · Rehovot, IL
• Yaki Eidelstein · Rehovot, IL

Key dates

• Filing date: Sep 8, 2011
• Grant date: Aug 23, 2016
• Expiry date: Sep 8, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2501/2321
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating a disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting a non-syngeneic cell or tissue graft to the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of cells comprising non-graft versus host (GVHD) inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, and further wherein the cells are either: (i) non-syngeneic with both the subject and the graft; or (ii) non-syngeneic with the graft and syngeneic with the subject, thereby treating the subject.